Want to see JP:4569 full AI Analyst Report?
4569 Stock Chart & Stats
¥1211.00
-¥69.00(-5.70%)
At close: 4:00 PM EDT
¥1211.00
-¥69.00(-5.70%)
Day’s Range― - ―
52-Week Range¥1,052.00 - ¥1,725.00
Previous CloseN/A
Volume266.10K
Average Volume (3M)127.03K
Market Cap
¥60.11B
Enterprise Value¥72.70K
Total Cash (Recent Filing)¥16.95B
Total Debt (Recent Filing)¥23.24B
Price to Earnings (P/E)30.2
Beta0.50
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.99%
Share Statistics
EPS (TTM)37.80
Shares Outstanding59,945,640
10 Day Avg. Volume147,840
30 Day Avg. Volume127,030
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)0.66
Price to Sales (P/S)0.75
P/FCF Ratio37.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)28.85
Revenue Forecast (FY)¥123.03B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and a steadily growing equity base give KYORIN durable financial flexibility. Conservative financing reduces refinancing risk and preserves capacity to fund R&D, pursue partnerships or withstand reimbursement shocks, supporting long-term operational resilience.
Focused Therapeutic FranchiseA clear focus on respiratory and infectious diseases builds deep clinical expertise, prescriber relationships and targeted R&D pipelines. This specialization supports predictable demand, licensing opportunities and competitive barriers that sustain revenues over multiple years.
Improved Operating Cash FlowThe recent recovery to positive operating and free cash flow strengthens KYORIN's ability to self-fund development, maintain dividends or invest in lifecycle management. While earlier swings exist, sustained cash generation would materially improve strategic optionality.
Bears Say
Profitability CompressionMaterial margin deterioration reduces internal cash available for R&D and weakens returns on commercial efforts. If driven by price/reimbursement or mix shifts rather than one-offs, compressed margins make the business more sensitive to cost and pricing pressures and threaten long-term reinvestment capacity.
Revenue Decline In FY2026A recent drop in revenues interrupts prior multi-year growth and signals vulnerability to pricing adjustments, competitive pressure or product lifecycle issues. Persistent top-line declines would reduce scale advantages and limit resource availability for new drug development or commercialization.
Volatile FCF And Weak ReturnsSwinging free cash flow and a sharp drop in ROE indicate inconsistent cash conversion and poor capital efficiency. This undermines predictable funding for R&D or dividends, raises the chance of external financing needs, and limits the company's ability to generate durable shareholder returns.
KYORIN Pharmaceutical Co.,Ltd. News
4569 FAQ
What was KYORIN Pharmaceutical Co.,Ltd.’s price range in the past 12 months?
KYORIN Pharmaceutical Co.,Ltd. lowest stock price was ¥1052.00 and its highest was ¥1725.00 in the past 12 months.
What is KYORIN Pharmaceutical Co.,Ltd.’s market cap?
KYORIN Pharmaceutical Co.,Ltd.’s market cap is ¥60.11B.
When is KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date?
KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date is Nov 09, 2026 which is in 94 days.
How were KYORIN Pharmaceutical Co.,Ltd.’s earnings last quarter?
KYORIN Pharmaceutical Co.,Ltd. released its earnings results on Jul 30, 2026. The company reported ¥14.35 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is KYORIN Pharmaceutical Co.,Ltd. overvalued?
According to Wall Street analysts KYORIN Pharmaceutical Co.,Ltd.’s price is currently Overvalued.
Does KYORIN Pharmaceutical Co.,Ltd. pay dividends?
KYORIN Pharmaceutical Co.,Ltd. pays a Semiannually dividend of ¥10 which represents an annual dividend yield of 4.99%. See more information on KYORIN Pharmaceutical Co.,Ltd. dividends here
What is KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate?
KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KYORIN Pharmaceutical Co.,Ltd. have?
KYORIN Pharmaceutical Co.,Ltd. has 59,945,640 shares outstanding.
What happened to KYORIN Pharmaceutical Co.,Ltd.’s price movement after its last earnings report?
KYORIN Pharmaceutical Co.,Ltd. reported an EPS of ¥14.35 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.575%.
Which hedge fund is a major shareholder of KYORIN Pharmaceutical Co.,Ltd.?
Currently, no hedge funds are holding shares in JP:4569
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
KYORIN Pharmaceutical Co.,Ltd.
Based in Tokyo, Japan, and founded in 1923, KYORIN Holdings, Inc. is a pharmaceutical enterprise engaged in the discovery, development, production, and worldwide distribution of both innovative prescription drugs and generic equivalents. Its diverse therapeutic catalog features medications such as Flutiform for asthma; Desalex, an antiallergic agent; and treatments like Beova, Uritos, and Imidafenacin KYORIN for overactive bladder. The company also offers Lasvic, a quinolone antibacterial; Pentasa for managing ulcerative colitis and Crohn's disease; Nasonex and Kipres for allergic rhinitis; and Mucodyne, a mucoregulating compound. Further pharmaceutical products include Montelukast KM, prescribed for bronchial asthma and allergic rhinitis. Beyond drugs, KYORIN Holdings markets specialized items like the GeneSoC real-time PCR system, disinfectant solutions such as Rubysta and Milton, over-the-counter remedies, diagnostic tools, industrial chemicals, and various reagents and intermediates. The company extends its services to include contract drug manufacturing and actively participates in early-stage research, including identifying and assessing candidate compounds, analyzing competitor technologies, and collecting data from clinical trials.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
Nippon Shinyaku Co., Ltd.
―